The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">acute_1</font> <font color="red">myeloid_1</font> <font color="red">leukemia_1</font> <font color="red">and_1</font> <font color="red">myelodysplastic_1</font> <font color="red">syndromes_1</font> <font color="red">:_1</font> <font color="red">a_1</font> <font color="red">Japanese_1</font> <font color="red">multicenter_1</font> <font color="red">randomized_1</font> <font color="red">,_1</font> <font color="red">controlled_1</font> <font color="red">study_1</font> <font color="red">._1</font> 
<br>
<br> We performed a <font color="red">randomized_1</font> <font color="red">,_1</font> <font color="red">controlled_1</font> <font color="red">study_1</font> <font color="red">comparing_1</font> <font color="red">the_1</font> <font color="red">prophylactic_2</font> <font color="red">effects_2</font> <font color="red">of_2</font> <font color="red">capsule_2</font> <font color="red">forms_2</font> <font color="red">of_2</font> <font color="red">fluconazole_2</font> <font color="red">(_2</font> <font color="red">n_2</font> <font color="red">=_2</font> <font color="red">110_2</font> <font color="red">)_2</font> <font color="red">and_2</font> <font color="red">itraconazole_2</font> <font color="red">(_2</font> <font color="red">n_2</font> <font color="red">=_2</font> <font color="red">108_2</font> <font color="red">)_2</font> <font color="red">in_2</font> <font color="red">patients_5</font> <font color="red">with_4</font> <font color="red">acute_4</font> <font color="red">myeloid_4</font> <font color="red">leukemia_4</font> <font color="red">(_4</font> <font color="red">AML_4</font> <font color="red">)_4</font> <font color="red">or_4</font> <font color="red">myelodysplastic_4</font> <font color="red">syndromes_4</font> <font color="red">(_4</font> <font color="red">MDS_4</font> <font color="red">)_4</font> <font color="red">during_3</font> <font color="red">and_3</font> <font color="red">after_3</font> <font color="red">chemotherapy_3</font> <font color="red">._3</font> There were <font color="red">4_1</font> <font color="red">cases_1</font> with possible systemic fungal infection in the <font color="red">itraconazole_1</font> <font color="red">group_1</font> <font color="red">,_1</font> and there were <font color="red">8_1</font> <font color="red">possible_1</font> <font color="red">and_1</font> <font color="red">3_1</font> <font color="red">probable_1</font> cases in the <font color="red">fluconazole_1</font> <font color="red">group_1</font> <font color="red">._1</font> Adverse events did not significantly differ in the <font color="red">2_1</font> <font color="red">groups_1</font> <font color="red">._1</font> In <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">MDS_1</font> or in the remission - induction phase of chemotherapy , the numbers of cases with probable or possible infections were lower in the <font color="red">itraconazole_1</font> <font color="red">group_1</font> than in the <font color="red">fluconazole_1</font> <font color="red">group_1</font> <font color="red">,_1</font> whereas no difference was seen in <font color="red">patients_1</font> with AML or in the consolidation phase of therapy . In <font color="red">patients_2</font> <font color="red">with_1</font> <font color="red">neutrophil_1</font> <font color="red">counts_1</font> <font color="red">of_1</font> <font color="red">>_1</font> <font color="red">0.1_1</font> <font color="red">x_1</font> <font color="red">10(9)/L_1</font> lasting for more than 4 weeks , the frequency of infection in the <font color="red">fluconazole_1</font> <font color="red">group_1</font> ( 5 of 9 patients ) was significantly higher than in the <font color="red">itraconazole_1</font> <font color="red">group_1</font> ( 0 of 7 patients ; P = .03 ) . Our results suggest that both drugs were well tolerated in <font color="red">patients_3</font> <font color="red">with_2</font> <font color="red">AML_2</font> <font color="red">or_2</font> <font color="red">MDS_2</font> <font color="red">who_2</font> <font color="red">received_2</font> <font color="red">chemotherapy_2</font> and that the efficacy of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of fluconazole .